Bayer Aktiengesellschaft (ETR:BAYN) pharma head Stefan Oelrich told attendees at the 2026 J.P. Morgan Healthcare Conference that the company’s pharmaceutical business is showing “clear proof points” of a turnaround, pointing to updated 2025 guidance, a reshaped product portfolio following major loss-of-exclusivity headwinds, and what he described as improved R&D productivity and organizational efficiency. 2025 performance […]